Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial (Q28211435)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial	scientific article

Statements

scholarly article

0 references

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial (English)

0 references

circulatory system

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michael Doherty

object named as

Michael Doherty

10

0 references

author name string

Michael E Farkouh

1

0 references

Howard Kirshner

2

0 references

Robert A Harrington

3

0 references

Sean Ruland

4

0 references

Freek W A Verheugt

5

0 references

Thomas J Schnitzer

6

0 references

Gerd R Burmester

7

0 references

Eduardo Mysler

8

0 references

Marc C Hochberg

9

0 references

Elena Ehrsam

11

0 references

Xavier Gitton

12

0 references

Gerhard Krammer

13

0 references

Bernhard Mellein

14

0 references

Alberto Gimona

15

0 references

Patrice Matchaba

16

0 references

Christopher J Hawkey

17

0 references

James H Chesebro

18

0 references

language of work or name

0 references

publication date

August 2004

1 reference

0 references

364

0 references

675-84

0 references

9435

0 references

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between naproxen use and protection against acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-Inflammatory drugs and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase-2 inhibitors: similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ibuprofen on cardioprotective effect of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916894-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(04)16894-3

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28211435&oldid=1955320351"